## Eduardo Pimenta

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5519220/publications.pdf

Version: 2024-02-01

172207 133063 3,603 63 29 59 citations h-index g-index papers 66 66 66 3330 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Effect of Diet on Serum Creatinine in Healthy Subjects During a Phase I Study. Journal of Clinical Medicine Research, 2016, 8, 836-839.	0.6	14
2	Drug Development for Hypertension: Do We Need Another Antihypertensive Agent for Resistant Hypertension?. Current Hypertension Reports, 2016, 18, 25.	1.5	6
3	Renin Angiotensin System Blockage Associates with Insertion/Deletion Polymorphism of Angiotensin-Converting Enzyme in Patients with Hypertensive Emergency. DNA and Cell Biology, 2013, 32, 541-548.	0.9	4
4	Diagnosis and management of primary aldosteronism: An updated review. Annals of Medicine, 2013, 45, 375-383.	1.5	111
5	Repeating adrenal vein sampling when neither aldosterone/cortisol ratio exceeds peripheral yields a high incidence of aldosterone-producing adenoma. Journal of Hypertension, 2013, 31, 2005-2009.	0.3	27
6	Obstructive Sleep Apnea and Sodium Intake: Response. Chest, 2013, 144, 720.	0.4	0
7	Increased Dietary Sodium Is Related to Severity of Obstructive Sleep Apnea in Patients With Resistant Hypertension and Hyperaldosteronism. Chest, 2013, 143, 978-983.	0.4	61
8	Factors Affecting the Aldosterone/Renin Ratio. Hormone and Metabolic Research, 2012, 44, 170-176.	0.7	164
9	Adverse Cardiovascular Outcomes of Corticosteroid Excess. Endocrinology, 2012, 153, 5137-5142.	1.4	30
10	Resistant Hypertension. Circulation, 2012, 125, 1594-1596.	1.6	173
11	Hypertensive crisis. Journal of Hypertension, 2012, 30, 882-883.	0.3	2
12	Management of hypertension in the elderly. Nature Reviews Cardiology, 2012, 9, 286-296.	6.1	54
13	Hypertension in women. Hypertension Research, 2012, 35, 148-152.	1.5	73
14	The Adrenal Vein Sampling International Study (AVIS) for Identifying the Major Subtypes of Primary Aldosteronism. Journal of Clinical Endocrinology and Metabolism, 2012, 97, 1606-1614.	1.8	310
15	Renal Sympathetic Denervation for Treatment of Hypertension. Current Treatment Options in Cardiovascular Medicine, 2012, 14, 127-135.	0.4	5
16	I posicionamento brasileiro sobre hipertensão arterial resistente. Arquivos Brasileiros De Cardiologia, 2012, 99, 576-585.	0.3	27
	Cardiologia, 2012, 77, 37 0 303.		
17	Characteristics of resistant hypertension: ageing, body mass index, hyperaldosteronism, cardiac hypertrophy and vascular stiffness. Journal of Human Hypertension, 2011, 25, 532-538.	1.0	68

#	Article	IF	CITATIONS
19	Gene Variation in Resistant Hypertension: Multilocus Analysis of the Angiotensin 1-Converting Enzyme, Angiotensinogen, and Endothelial Nitric Oxide Synthase Genes. DNA and Cell Biology, 2011, 30, 555-564.	0.9	30
20	Treatment of hypertension in the emergency department. Journal of the American Society of Hypertension, 2011, 5, 366-377.	2.3	29
21	Effect of Contraceptives on Aldosterone/Renin Ratio May Vary According to the Components of Contraceptive, Renin Assay Method, and Possibly Route of Administration. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1797-1804.	1.8	80
22	Quality of Life in Patients with Bilateral Primary Aldosteronism before and during Treatment with Spironolactone and/or Amiloride, Including a Comparison with Our Previously Published Results in Those with Unilateral Disease Treated Surgically. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2904-2911.	1.8	90
23	Cardiac Dimensions Are Largely Determined by Dietary Salt in Patients with Primary Aldosteronism: Results of a Case-Control Study. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 2813-2820.	1.8	72
24	What is new in the management of resistant hypertension?. Therapy: Open Access in Clinical Medicine, 2011, 8, 261-273.	0.2	2
25	Effects of Two Selective Serotonin Reuptake Inhibitor Antidepressants, Sertraline and Escitalopram, on Aldosterone/Renin Ratio in Normotensive Depressed Male Patients. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1039-1045.	1.8	41
26	Are Women More at Risk of False-Positive Primary Aldosteronism Screening and Unnecessary Suppression Testing than Men?. Journal of Clinical Endocrinology and Metabolism, 2011, 96, E340-E346.	1.8	86
27	Hyperreninemic hypertension following presumed abdominal trauma. Nature Reviews Nephrology, 2011, 7, 730-734.	4.1	5
28	Increasing adherence: is that enough?. Hypertension Research, 2010, 33, 411-413.	1.5	2
29	Is There a Place on the Shelf for Aliskiren?. Current Cardiovascular Risk Reports, 2010, 4, 264-270.	0.8	0
30	Efficacy of an Olmesartan Medoxomil–Based Treatment Algorithm in Patients Stratified by Age, Race, or Sex. Journal of Clinical Hypertension, 2010, 12, 3-13.	1.0	18
31	Severity of Obstructive Sleep Apnea is Related to Aldosterone Status in Subjects with Resistant Hypertension. Journal of Clinical Sleep Medicine, 2010, 06, 363-368.	1.4	123
32	Response to "Effective―Plasma Renin Activity: A Derived Measure for Assessing Residual Plasma Renin Activity in Patients Taking Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers. Hypertension, 2010, 55, .	1.3	0
33	Salt and Aldosterone. Hypertension, 2010, 56, 804-805.	1.3	15
34	Rapid Reversal of Left Ventricular Hypertrophy and Intracardiac Volume Overload in Patients With Resistant Hypertension and Hyperaldosteronism. Hypertension, 2010, 55, 1137-1142.	1.3	137
35	Treatment of resistant hypertension. Journal of Hypertension, 2010, 28, 2194-2195.	0.3	14
36	Effect of Atenolol on Aldosterone/Renin Ratio Calculated by Both Plasma Renin Activity and Direct Renin Concentration in Healthy Male Volunteers. Journal of Clinical Endocrinology and Metabolism, 2010, 95, 3201-3206.	1.8	44

#	Article	IF	CITATIONS
37	Should we send our kids to the gym?. Hypertension Research, 2010, 33, 880-882.	1.5	1
38	Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. Journal of Human Hypertension, 2010, 24, 532-537.	1.0	252
39	Prehypertension: epidemiology, consequences and treatment. Nature Reviews Nephrology, 2010, 6, 21-30.	4.1	71
40	Laboratory investigation of primary aldosteronism. Clinical Biochemist Reviews, 2010, 31, 39-56.	3.3	63
41	Severity of obstructive sleep apnea is related to aldosterone status in subjects with resistant hypertension. Journal of Clinical Sleep Medicine, 2010, 6, 363-8.	1.4	66
42	Uncontrolled hypertension: beyond pharmacological treatment. Hypertension Research, 2009, 32, 729-731.	1.5	4
43	Aldosterone and Metabolic Dysfunction. Hypertension, 2009, 53, 585-586.	1.3	18
44	Effects of Dietary Sodium Reduction on Blood Pressure in Subjects With Resistant Hypertension. Hypertension, 2009, 54, 475-481.	1.3	474
45	Sleep Apnea, Aldosterone, and Resistant Hypertension. Progress in Cardiovascular Diseases, 2009, 51, 371-380.	1.6	59
46	Aldosterone Excess or Escape: Treating Resistant Hypertension. Journal of Clinical Hypertension, 2009, 11, 245-252.	1.0	25
47	Aldosterone and Cardiovascular Disease. Current Problems in Cardiology, 2009, 34, 51-84.	1.1	51
48	Sevikar®: combination therapy for the treatment of hypertension. Advances in Therapy, 2009, 26, 1-11.	1.3	1
49	Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors. Therapeutics and Clinical Risk Management, 2009, 5, 459.	0.9	15
50	Clinical trials report. Current Hypertension Reports, 2008, 10, 213-215.	1.5	0
51	Mechanisms and Treatment of Resistant Hypertension. Journal of Clinical Hypertension, 2008, 10, 239-244.	1.0	42
52	Renin Inhibitors: Novel Agents for Renoprotection or a Better Angiotensin Receptor Blocker for Blood Pressure Lowering?. Cardiology Clinics, 2008, 26, 527-535.	0.9	11
53	Relation of Dietary Salt and Aldosterone to Urinary Protein Excretion in Subjects With Resistant Hypertension. Hypertension, 2008, 51, 339-344.	1.3	69
54	Characterization of Resistant Hypertension <subtitle>Association Between Resistant Hypertension, Aldosterone, and Persistent Intravascular Volume Expansion</subtitle> . Archives of Internal Medicine, 2008, 168, 1159.	4.3	254

#	Article	IF	CITATIONS
55	Fixed combinations in the management of hypertension: patient perspectives and rationale for development and utility of the olmesartan – amlodipine combination. Vascular Health and Risk Management, 2008, Volume 4, 653-654.	1.0	31
56	Should we prefer different drugs to treat hypertension in older and younger adults? Practical implications of clinical trials: American perspective., 2008, 118, 508-12.		0
57	Aldosterone excess and resistance to 24-h blood pressure control. Journal of Hypertension, 2007, 25, 2131-2137.	0.3	36
58	SÃndrome metabólica em pacientes submetidos à cirurgia de revascularização miocárdica: prevalência e marcador de morbi-mortalidade no perÃodo intra-hospitalar e após 30 dias. Arquivos Brasileiros De Cardiologia, 2007, 88, 413-417.	0.3	10
59	Resistant hypertension and aldosteronism. Current Hypertension Reports, 2007, 9, 353-359.	1.5	46
60	Mecanismos e tratamento da hipertens $\tilde{A}$ £o arterial refrat $\tilde{A}$ ¡ria. Arquivos Brasileiros De Cardiologia, 2007, 88, 683-692.	0.3	13
61	Primary Aldosteronism: Diagnosis and Treatment. Journal of Clinical Hypertension, 2006, 8, 887-893.	1.0	27
62	Aldosterone, Dietary Salt, and Renal Disease. Hypertension, 2006, 48, 209-210.	1.3	18
63	Hemarthrosis of the knees following streptokinase therapy for acute myocardial infarction. Arquivos Brasileiros De Cardiologia, 2003, 80, 641-642.	0.3	1